Provectus Biopharmaceuticals (STU:PXY) Moat Score: 3/10 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PXY Provectus Biopharmaceuticals Inc STU:PXY
35 GF Score
Price €0.05
! 3 Warning Signs
View Full Analysis

What is Provectus Biopharmaceuticals Moat Score?

Provectus Biopharmaceuticals STU:PXY 35 Moat Score is 3 as of Aug. 04, 2026. GuruFocus rates STU:PXY with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,394 Biotechnology companies, Provectus Biopharmaceuticals ranks better than 75.61% on this metric.

Provectus Biopharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Provectus Biopharmaceuticals has No Moat: Provectus Biopharmaceuticals has some intellectual property in the form of patents, but lacks market leadership, strong brand strength, or significant regulatory barriers. The biotech industry is highly competitive, and the company's advantages are transient and not durable.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Provectus Biopharmaceuticals might have No Moat - Very weak/transient advantages.

Provectus Biopharmaceuticals  (STU:PXY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Provectus Biopharmaceuticals Moat Score Related Terms

STU:PXY vs PSTV, ALGS, ATNM: Moat Score Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provectus Biopharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Moat Score falls into.


STU:PXY
35GF Score
Provectus Biopharmaceuticals Inc STU:PXY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Provectus Biopharmaceuticals (STU:PXY) has a Moat Score of 3 as of Aug. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #340 out of 1394 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Provectus Biopharmaceuticals' Moat Score too high?
Provectus Biopharmaceuticals' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Provectus Biopharmaceuticals' value of 3 is 50% above this industry median. Based on the distribution chart, Provectus Biopharmaceuticals ranks #340 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Provectus Biopharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Provectus Biopharmaceuticals' Moat Score compare to PSTV and ALGS?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #340 out of 1394 companies for Moat Score. This places Provectus Biopharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Provectus Biopharmaceuticals' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Provectus Biopharmaceuticals's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provectus Biopharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (STU:PXY) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Provectus Biopharmaceuticals' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Provectus Biopharmaceuticals (STU:PXY), the current Moat Score is 3 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provectus Biopharmaceuticals Business Description

Other Exchanges PVCT:USA
Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
35GF Score

Get the complete analysis for STU:PXY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price